Table 1 Dosage, duration, outcome, and toxicity of intravenous colistimethate sodium in critically ill patients
From: Renal and neurological side effects of colistin in critically ill patients
Author | Patients (N) | APACHE II (mean ± SD) | CMS dose/duration [mean ± SD or median (range)] | Clinical cure N (%) | Nephrotoxicity N (%) | Neurotoxicity |
|---|---|---|---|---|---|---|
Levin | 59 (60 infections) | 13.1 ± 7 | 152.8 mg ± 62.8 mg 12.6 ± 6.8 days | 35 (58.3) | 22 (37) | none |
Markou | 24 (26 infections) | 20.6 (mean) | 3 MIUq8h 13.5 days (4-24 days) | 17 (65.4) | 3 (14.5) | none |
Garnacho- Montero | 21 | 19.6 ± 7.2 | 2.5 mg-5 mg/kg/day 14.7 ± 4.1days | 12 (57.1) | 5 (24) | none |
Michalopoulos | 43 | 25.8 ± 7.7 | 3 MIUq8h 18.6 ± 5.8 days | 32 (74) | 8 (18.6) | none |
Falagas | 17 (19 infections) | 14 (median) 43.4 ± 14.6 days | 4.4 MIU ± 2.1 MIU | 14 (74) | 1 (5.2) | 1 |
Kasiakou | 50 (54 infections) | 16.1 ± 6.1 | 4.5 MIU ± 2.3 MIU 21.3 ± 16 days | 36 (66.7) | 4 (8) | 1a |
Reina | 55 | 21 ± 7 | 5 mg/kg (max 300 mg/day) 13 ± 5 days | NA | 0 (0) | none |
Petrosillob | 14 | NA | 2 MIUq8h 12 days (mean) | 9 (64) | 1 (7.1) | none |
Kallel | 75 (78 infections) | NA (SAPS II 37 ± 14) |  | 5.5 MIU ± 1.1 MIU 9.3 ± 3.8 days | 60 (76.9) 7/52 (13.5) | 1 |
Koomanachai | 78 | 21.9 (mean) | 179.6 mg/day (mean) 11.9 days (mean) | 63 (80.8) | 24 (30.8) | none |
Betrosian | 15 | 14 ± 2 | 5.83 MIU ± 2.3 MIU duration NA | 9 (60) | 5 (33) | none |
Bassettib | 29 | 17 ± 3.7 | 2 MIUq8h 17.7 ± 10.4 days | 22 (76) | 3 (10) | none |
Kallel | 60 | NA (SAPS II 35 ± 12) | 2 MIUq8h 9.5 ± 3.8 days | 45 (75) | 0 (0) | NA |
Falagas | 21 | 19 ± 4 | 5.5 MIU ± 1.9 MIU 17.7 ± 11.7 days | 11 (52.4) | 3 (14.3) | none |
Falagas | 14 (CMS mono) | 14.3 ± 7.4 | 4.6 MIU ± 2.3 MIU 14.2 ± 7.3 days | 12 (85.7) | 0 (0) | NA |
|  | 57 (CMS+MERO) | 15.4 ± 6.6 | 5.5 MIU ± 2.2 MIU 17.8 ± 11.4 days | 39 (68.4) | 4 (7) | NA |
Pintado | 60 | 11.2 ± 7.7 | 4.42 MIU ± 1.39 MIU 20 ± 9.2 days | 43 (71.7) | 6/55 (10.9) | none |
Sabuda | 12 | NA | 3.7 mg/kg 14.7 ± 13.8 days | 8 (66.7) | 5 (41.6) | 4 cases |
Huang | 15 | 14.7 ± 4.5 | 1.28 MIU ± 0.25 MIU 22.3 ± 6.2 days | 11 (73.3) | 0 (0) | none |
Hartzell | 66 | 8.3 ± 6.5 | 4.3 ± 1.2 mg/kg/day 15.8 ± 9.2 days | NA | 30 (45) | 2 cases |
Kim | 42 (47 infections) | NA | 2.25 g (0.6-8.7g)c 16.6 ± 14.8 dayse | 10/15 (66)d | 15 (31.9) | none |
Kwon | 71 | NA | 4.6 mg/kg (median) 13 days (7-22 days) | NA | 38 (53.5) | none |
Cheng | 115f | 6 (median) | dose NA 12 ± 7daysg | 59 (51) | 12/84 (14) | 4 cases |
Song | 10 | NA | 150 mg q12h 8.1 ± 1.8 days | 7 (70) | 0 (0) | none |
Falagash | 258 | 17 (range 2-39) | up to 3 MIUq8h mean 17.9 days (10-22) | 204 (79.1) | 26 (10) | NA |
Kofteridis | 43 | 17.7 ±7.6 | 3 MIUq8h median 10 days (4-36 days) | 14 (32.5) | 8 (19) | none |
DeRyke | 30 | 13 (range 7-18)i | 5.1 ± 2 mg/kg/dayj median 8 days (3-24) | NA | 10 (33%) | none |